Literature DB >> 27476178

Use of freeze-dried bone allografts in revision total hip arthroplasty.

Maurice Caltran1, Claude Savornin2, Patrick Le Couteur3, Paul Jouan3, Philippe Deroche4, Jean-François Vinceneux4, Laurence Barnouin5.   

Abstract

Acetabular loosenings with severe bone loss require a large amount of graft material to fill the defect. Although all donors are systematically subjected to serologic screening, bone allografts that are chemically processed, freeze-dried, and radiosterilized ensure a higher level of microbiological safety than radiosterilised deep-frozen allografts. The bone allograft used in this study meets this requirement. Therefore, it was both interesting and important to evaluate its outcome in revision acetabuloplasty. This phase II multi-centre study involves 44 revision total hip replacements (35 evaluable) in patients with acetabular bone defects who received allografts obtained from femoral heads harvested from living donors. The results obtained at 40 months follow-up confirmed that reconstructions using a small amount of graft material have a satisfactory outcome. Where an allograft is used in association with an acetabular ring, good primary stability is provided by the ring and secondary stability is ensured by graft incorporation (which, in our study, has often shown to be enhanced by the use of bone cement). The advantages of this type of bone allograft are its greater ease of use and storage at room temperature.

Entities:  

Keywords:  Acetabular reconstruction; Bone allograft; Revision total hip arthroplasty

Year:  2002        PMID: 27476178     DOI: 10.1007/s00590-002-0051-4

Source DB:  PubMed          Journal:  Eur J Orthop Surg Traumatol        ISSN: 1633-8065


  28 in total

1.  Total acetabular transplant allograft reconstruction of the severely deficient acetabulum.

Authors:  M S Bradford; W G Paprosky
Journal:  Semin Arthroplasty       Date:  1995-04

2.  HIV-1 from a seronegative transplant donor.

Authors:  M Clerici; J A Berzofsky; G M Shearer; J V Giorgi; C Tacket
Journal:  N Engl J Med       Date:  1992-08-20       Impact factor: 91.245

3.  [Acetabular reconstruction using bone allograft in the revision of total hip prosthesis].

Authors:  F Morand; J P Clarac; L E Gayet; P Pries
Journal:  Rev Chir Orthop Reparatrice Appar Mot       Date:  1998-04

4.  Factors influencing stability at the interface between a porous surface and cancellous bone: a finite element analysis of a canine in vivo micromotion experiment.

Authors:  B S Ramamurti; T E Orr; C R Bragdon; J D Lowenstein; M Jasty; W H Harris
Journal:  J Biomed Mater Res       Date:  1997-08

5.  High failure rate of bulk femoral head allografts in total hip acetabular reconstructions at 10 years.

Authors:  L M Kwong; M Jasty; W H Harris
Journal:  J Arthroplasty       Date:  1993-08       Impact factor: 4.757

6.  Effects of gamma irradiation on the human immunodeficiency virus. A study in frozen human bone-patellar ligament-bone grafts obtained from infected cadavera.

Authors:  B M Fideler; C T Vangsness; T Moore; Z Li; S Rasheed
Journal:  J Bone Joint Surg Am       Date:  1994-07       Impact factor: 5.284

Review 7.  Donor selection, testing, and inactivation of the HIV virus in freeze-dried bone allografts.

Authors:  J T Mellonig
Journal:  Pract Periodontics Aesthet Dent       Date:  1995-08

8.  Salvage total hip reconstruction in patients with major acetabular bone deficiency using structural femoral head allografts.

Authors:  M Jasty; W H Harris
Journal:  J Bone Joint Surg Br       Date:  1990-01

9.  Classification and reconstruction in revision acetabular arthroplasty with bone stock deficiency.

Authors:  D Garbuz; E Morsi; N Mohamed; A E Gross
Journal:  Clin Orthop Relat Res       Date:  1996-03       Impact factor: 4.176

10.  Revision of the acetabular component without cement after total hip arthroplasty. Three to six-year follow-up.

Authors:  D E Padgett; L Kull; A Rosenberg; D R Sumner; J O Galante
Journal:  J Bone Joint Surg Am       Date:  1993-05       Impact factor: 5.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.